Gastrointestinal Cancer

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.

Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.

Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

177Lu-edotreotide prolonged PFS vs everolimus in patients with inoperable, progressive, grade 1 or 2 gastroenteropancreatic neuroendocrine tumors.

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.